Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection

Ítems similars

• Safety of CAR T-cell therapy in kidney transplant recipients
  per: Mamlouk, Omar, et al.
  Publicat: (2021)
• The promise of CAR T-cell therapy in aggressive B-cell lymphoma
  per: Nair, Ranjit, et al.
  Publicat: (2018)
• Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy
  per: Elizabeth J Shpall, et al.
  Publicat: (2025-10-01)
• Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma
  per: Strati, Paolo, et al.
  Publicat: (2020)
• Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma
  per: Strati, Paolo, et al.
  Publicat: (2021)